Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
MOH Issues Guideline for Medical Payment Reform of NRCMS
In an attempt to push forward the medical payment/reimbursement system reform, the MOH, the NDRC and the MOF jointly released a new document, Guidelines for Implementing ... (5/15/2012)
   
Government: Big Pharma's Best Friend in Emerging Markets? (External) (5/15/2012)
Review of Chinese Hospital Drug Market Trends in 2011 (5/10/2012)
Review of Anti-infective Consumption by Chinese Hospitals in 2011 (5/10/2012)
Review of Chinese Pharmaceutical Industry Performance in 2011 (5/9/2012)
Business As Usual for Chinese Pharma Amid Healthcare Reform Turbulences? (4/24/2012)
Sparring Over Sorafenib: How Will Natco's Move against Bayer Affect Pharma Licensing? (External) (4/19/2012)
Outsourcing Trends in China (External) (4/18/2012)
Review of Chinese Pharma Deals, R&D and Regulatory Developments in Q1/2012 (4/16/2012)
Resourcing Clinical Research Programs in China (4/12/2012)
Review of Chinese Hospital Drug Consumption Patterns In 2011 (4/9/2012)
China's Gravity-defying Economy: How Hard Will It Fall? (External) (3/29/2012)
Pharma Industry Resists "Anhui Model" Under Increasing Pricing Pressure (3/26/2012)
SciClone Pharma Rises on China Business Focus Despite R&D Drawbacks (3/16/2012)
Review of the Chinese Pharmaceutical Retail Market 2009-2011 (3/13/2012)
Health Reform Turbulences Resumed After the Chinese New Year (3/12/2012)
Chinese Urban Retail OTC Market on Stead...  (5/16/2012)
MOFCOM Reports Steady Growth of the Chin...  (5/16/2012)
API Sector Performance in 2011 and 1Q/20...  (5/16/2012)
NBS: Chinese Pharma Industry Growth Slow...  (5/16/2012)
China Issues New Rules to Streamline Med...  (5/16/2012)
BMS Announces US$20M Investment Plan to ...  (5/16/2012)
MOH Issues Guideline for Medical Payment...  (5/15/2012)
NDRC to Introduce a New Guideline for Re...  (5/15/2012)
Health Minister Chen Zhu: China to Promo...  (5/15/2012)
Recent Executive Moves  (5/15/2012)
BMS Enters Strategic Partnership with Ts...  (5/15/2012)
China Shenghuo Pharma Opts to Delist fro...  (5/14/2012)
Data Snapshot: Chinese Market Shares by ...  (5/14/2012)
CDE Hires Two New Senior Reviewers  (5/14/2012)
The MOH Holds Annual Clinical Pathway Ma...  (5/14/2012)
Sanofi Performance Bolstered by Strong Growth in Emergin...
Abbott's Humira set to become the top-selling drug globa...
Global biosimilars market to reach US$17.9 billion by 20...
Biocon inaugurates the largest biosicence research facil...
Big pharma files fewer patents in recent years
Chinese Urban Retail OTC Market on Steady Growth in 2011
Data Snapshot: Chinese Market Shares by Dosage Forms with Empha...
IMS: Chinese OTC Drug Market on Steady Growth (Updated)
Market share of top 100 drugs by hospital sales fell consistent...
Chinese OTC drug market development lags behind overall pharma ...
MOFCOM Reports Steady Growth of the Chinese Pharma Distribut...
NBS: Chinese Pharma Industry Growth Slows in the First Quart...
BMS Announces US$20M Investment Plan to Expand Manufacturing...
BMS Enters Strategic Partnership with Tsinghua U for Drug Di...
China Shenghuo Pharma Opts to Delist from NYSE Amex
MOH Issues "Provisions for Clinical Application of Antib...
SFDA Revises the Package Insert of Orlistat
SFDA Revises the Package Insert of Pioglitazone
MOH Issues the 3rd Draft of GSP Revision for Public Comm...
The Proposed NDRC Rule for Distribution Margin Is Expect...
A Former Sanofi Employee Sentenced to 18 Months in Prison fo...
China Sets Up Two Study/Demo Centers for Pharma IPR
Novartis faces Chinese lawsuit for alleged ADRs and ADR info...
SFDA terminates administrative protection of two Roche produ...
Chinese expert calls for revision of the Drug Administration...
API Sector Performance in 2011 and 1Q/2012
Novozymes Begins Supply of Hyaluronic Acid from China
New Data Predicts High Growth for the Global API Market
Update on International Regulatory Compliance of China-b...
Qianjiang YongAn Pharma fined CNY 3.8M for pollution and...
Generon Initiates Phase II Global Trial for G-CSF after ...
Chinese Scientists Eyes Development of a HIV-blocking Ge...
MicuRx Pharmaceuticals Completes Phase I Trial for New A...
First formulated TCM gains drug approval in regulated ma...
Haikou Pharma and Chongqing Sino to initiate phase II cl...
China Issues New Rules to Streamline Medical Service Pri...
MOH Issues Guideline for Medical Payment Reform of NRCMS...
NDRC to Introduce a New Guideline for Reform of Drug Pri...
Health Minister Chen Zhu: China to Promote Use of Advanc...
The MOH Holds Annual Clinical Pathway Management Confere...
Recent Executive Moves
CDE Hires Two New Senior Reviewers
Another Zhejiang FDA Boss in Court for Corruption
Latest Executive Moves
China Biological Products Appoints New CFO
Upcoming Event: Pharmacovigilance Asia 2012
Upcoming Event: Healthcare in China
Upcoming Event: BioPharma Convention Asia 2013
Upcoming Event: World Stem Cells & Regenerative Medi...
Upcoming Event: Biopharma India Convention 2012
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON will publish China Pharm...
  WiCON officially publishes Chi...
  Pharma China adds one more dis...
  Pharma China adds another dist...
  Testimonials from subscribers ...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links